RE:RE:JDRF tweeting about SernovaMed agree, all those years the attention was on
Viacyte and that focus is starting to shift, cant ignore the science.
JDRF can be thought of as a sentiment tracker for TD1 cure.
I enjoyed the quality times we have all had over the years. It's actually engaging to discuss something with longs that have a deep understanding of the science and potential here positive or negative. I can't be bothered to waste my time on trolls that came late to the party and got burnt on some volatility swings. They will be squelched on the next leg up. I'm happy enough with that.
If they really cared about valuation justice they would be chasing after all the preclinical companies that are valued in the billions.